Clinical trial Archives

News and Trends 13 Sep 2022

Ilya Pharma partners with US Defense Department for wound healing drug

A drug to accelerate wound healing and reduced scar volume has had a major breakthrough shown in results from a first in human trial. Ilya Pharma, a clinical stage immunotherapy company presented the findings at the US Defense Department’s (DoD) Military Health System Research Symposium (MHSRS) Conference in Florida and made the announcement yesterday (September […]

September 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

Starpharma announces new data for prostate cancer trial

Cabazitaxel (Jevtana, Sanofi) is a chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel that has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. In a poster presentation at ESMO […]

September 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Himalaya Therapeutics publishes data on cancer treatment

Himalaya Therapeutics has given an interim topline data update from its phase 2 study of HTBA3011 (mecbotamab vedotin) in non-small cell lung cancer (NSCLC) and certain sarcomas. In August, Himalaya’s collaboration partner, BioAtla publicly announced operational updates on the ongoing global clinical trials for HTBA3011 in patients with AXL-positive NSCLC who have previously failed PD-1/L1, […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

PDC*line Pharma presents results from phase I/II trial

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Enterome presents more data on therapeutic cancer treatment

Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Astellas, Seagen and Merck give details on urothelial cancer treatment

Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […]

September 12, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

Clinical oncology company Ayala Pharmaceuticals, Inc. has announced updated, positive interim results from part A of its ongoing RINGSIDE pivotal phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. Ayala Pharmaceutical’s AL102 is a selective, oral gamma-secretase inhibitor. The data are being featured in an oral presentation at the European Society for […]

September 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

The first patient has been enrolled in a phase 3 study of a treatment for type 1A Charcot-Marie-Tooth Disease (CMT1A) in the U.S., it was announced today (September 12). Charcot-Marie-Tooth disease is a group of inherited conditions that damage the peripheral nerves and a treatment is being developed by French biopharmaceutical company, Pharnext. The PREMIER […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Reveal Genomics reveals more HER2DX breast cancer validation data

Reveal Genomics, S.L. says it has received more validation of HER2DX, the world’s first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the data at the European Society of Medical Oncology Congress 2022 in Paris, France. The data obtained from the analysis of tumor samples from the PerELISA […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Shasqi moves to phase 2 solid tumor study

Shasqi, a clinical-stage biotechnology company developing oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform says it has opened the phase 2 part of its phase 1/2a clinical study to further assess SQ3370 in anthracycline-naïve patients. The phase 2 study follows the company’s presentation at the European Society for Medical Oncology (ESMO) […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Sep 2022

Fight against malaria boosted by findings from a vaccine trial showing high efficacy

Hope that malaria could be eradicated forever has been given a boost after new findings from a vaccine trial showed a high-rate of efficacy. Researchers from the University of Oxford and their partners have yesterday (September 8) reported new findings from their malaria vaccine R21/Matrix-M phase 2b trials following the administration of a booster dose. […]

September 9, 2022 - 4 minutesmins - By Liza Laws

Horizone Therapeutics, Eye disease, eye, eyes

News and Trends 9 Sep 2022

Improved vision with less eye injections for patients after primary endpoints met in trials

The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]

September 9, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Ilya Pharma partners with US Defense Department for wound healing drug

Starpharma announces new data for prostate cancer trial

Himalaya Therapeutics publishes data on cancer treatment

PDC*line Pharma presents results from phase I/II trial

Enterome presents more data on therapeutic cancer treatment

Astellas, Seagen and Merck give details on urothelial cancer treatment

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

Reveal Genomics reveals more HER2DX breast cancer validation data

Shasqi moves to phase 2 solid tumor study

Fight against malaria boosted by findings from a vaccine trial showing high efficacy

Improved vision with less eye injections for patients after primary endpoints met in trials

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!